5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | SELL | NEUTRAL | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.91▲ | 0.92▲ | 0.92▼ | 0.91▲ | 0.87▲ |
MA10 | 0.91▲ | 0.92▼ | 0.93▼ | 0.88▲ | 0.86▲ |
MA20 | 0.92▼ | 0.93▼ | 0.92▼ | 0.87▲ | 1.05▼ |
MA50 | 0.92▼ | 0.90▲ | 0.87▲ | 0.85▲ | 1.52▼ |
MA100 | 0.89▲ | 0.86▲ | 0.87▲ | 1.06▼ | 1.55▼ |
MA200 | 0.87▲ | 0.87▲ | 0.85▲ | 1.52▼ | 2.27▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | -0.005▼ | -0.004▼ | 0.011▲ | 0.023▲ |
RSI | 47.852▼ | 49.937▼ | 52.971▲ | 58.036▲ | 42.669▼ |
STOCH | 32.485 | 9.043▼ | 27.827 | 73.321 | 44.284 |
WILL %R | -42.593 | -85.446▼ | -67.368 | -17.782▲ | -82.443▼ |
CCI | 45.535 | -71.398 | -61.795 | 117.055▲ | 57.961 |
Saturday, May 31, 2025 07:54 PM
Find the latest institutional holdings data for InflaRx N.V. Common Stock (IFRX) including shareholders, ownership summaries, and holding activities at Nasdaq.com.
|
Wednesday, May 28, 2025 05:00 PM
InflaRx (IFRX) stock plummeted on Wednesday after the clinical-stage biopharmaceutical company announced a halt to its Phase 3 trial of vilobelimab to treat pyoderma gangrenosum.
|
Thursday, May 08, 2025 11:09 PM
Fintel reports that on May 8, 2025, Oppenheimer initiated coverage of InflaRx N.V. (NasdaqGS:IFRX) with a Outperform recommendation. Analyst Price Forecast Suggests 502.53% Upside As of May 7 ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/08/25 | 0.95 | 0.9577 | 0.907 | 0.92 | 428,102 |
25/08/25 | 0.894 | 0.9588 | 0.87 | 0.9209 | 506,048 |
22/08/25 | 0.89 | 0.9487 | 0.82 | 0.9135 | 606,073 |
21/08/25 | 0.8761 | 0.90 | 0.84 | 0.898 | 272,258 |
20/08/25 | 0.89 | 0.9199 | 0.85 | 0.8929 | 96,768 |
19/08/25 | 0.92 | 0.9499 | 0.84 | 0.8821 | 274,705 |
18/08/25 | 0.88 | 0.9124 | 0.85 | 0.9124 | 125,967 |
15/08/25 | 0.82 | 0.8629 | 0.80 | 0.8629 | 197,880 |
14/08/25 | 0.794 | 0.8399 | 0.779 | 0.8273 | 196,023 |
13/08/25 | 0.84 | 0.84 | 0.7946 | 0.816 | 202,883 |
|
|
||||
|
|
||||
|
|